Claims for Patent: 7,914,817

Summary for Patent: 7,914,817

Title:	Treatment of inflammatory bowel disease
Abstract:	Patients suffering from inflammatory bowel disease such as Crohn\'s disease or ulcerative colitis are treated either orally or intravenously with methylol transfer agents, such as taurolidine and/or taurultam. These agents can be used in combination with other drugs thereby allowing the use of smaller amounts of the other drugs and limiting unwanted side effects.
Inventor(s):	Redmond; H. Paul (Wilton, IE), Pfirrmann; Rolf W. (Lucerne, CH)
Assignee:	Ed. Geistlich Soehne AG fuer Chemische Industrie (Wolhusen, CH)
Application Number:	11/039,958
Patent Claims:	1. A method of treating ulcerative colitis or Crohn's disease in a patient comprising orally administering to said patient an effective amount of a methylol transfer agent having activity substantially the same as taurolidine or taurultum, wherein said methylol transfer agent is administered to said patient at an oral dose of about 100-1000 mg. 2. The method of claim 1 wherein said agent is selected from the group consisting of taurolidine, taurultam, and mixtures thereof. 3. The method of claim 2, wherein taurolidine is administered to said patient at an oral dose of about 100-1000 mg. 4. The method of claim 3 wherein said taurolidine is administered to said patient daily. 5. The method of claim 4 wherein about 20 g of said taurolidine is administered to said patient daily. 6. The method of claim 1 wherein said agent is further administered intravenously to said patient. 7. The method of claim 1 wherein infliximab in addition to said methylol transfer agent is administered to said patient.

Details for Patent 7,914,817

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2020-01-05